At the start of the coronavirus pandemic in March, most research labs were closed in order to prevent the spread of COVID-19. After working from home for more than 2 months, labs slowly start to reopen. But, how do you make sure to adhere to all social distancing measures while using your time in the lab as efficiently as possible? Many lab managers and research technicians have tried to find the best way to set up the lab in order to let all scientists make a safe comeback. PhD-candidates and post-docs, on the other hand, have to find ways to use their time in the lab as efficiently as possible.
As part of the scientific community, we understands the challenges you might face while getting back to the lab under the ‘new normal’ conditions. To help out everyone who is trying to figure out how to maintain a safe distance in the lab, our application specialists would like to share their tips and tricks with you. In this 45-minute webinar, we will share common measures that are taken in labs worldwide to adhere to the social distancing measures. Next to this, we will discuss some tools to help you get the most out of the limited amount of time that you can spend in the lab now. Examples include tools to help you keep enough distance from colleagues, reserve equipment and train students. Remote monitoring of cell cultures and experiments will also be addressed in the webinar.
Inge Thijssen, PhD.
Fusce ut magna imperdiet, varius orci in, imperdiet nulla. Vestibulum tincidunt dignissim gravida. Nulla aliquam risus sed urna lobortis scelerisque. Curabitur ultricies nisi sed leo mattis, quis luctus orci semper. Nullam volutpat dapibus quam, sed convallis magna venenatis vitae. Sed condimentum massa libero, laoreet efficitur velit congue at. Interdum et malesuada fames ac ante ipsum primis in faucibus. Integer facilisis quam in metus facilisis egestas. Quisque tristique dui ut bibendum suscipit.
- Dr. Dennis Plenker studied molecular biomedicine at the University of Bonn, Germany, and performed drug screens in primary glioblastoma cells for his diploma thesis. For his Ph.D. he transferred to the Department of Translational Genomics at the University of Cologne and characterized the first oncogenic gene fusion that involves a ligand (CD74-NRG1). Dennis did a postdoc in the Department of Molecular Pathology where he showed how to effectively treat RET-fusion positive tumors and how to treat tumors with rearrangements in the MET oncogene. Dennis moved to CSHL in 2017 and manages the human organoid platform in the Tuveson lab focusing on advancing organoid technology and understanding resistance in pancreatic cancer.
- Dr Ruchi Sharma is driven by her passion for taking the benefits of research and applying them to products and technology in order to make a significant and positive difference in the real world. She is one to watch entrepreneur of 2020 in UK and is leading prestigious grants and multinational partnerships. Dr Sharma obtained a PhD from the world-renowned Roslin Institute at the University of Edinburgh, followed by a post-doctorate in the exciting field of cellular reprogramming at the University of Cambridge. With a firm focus on partnerships and collaboration, Dr Sharma firmly believes that together, we can create a better world.
- Dr. René M. Overmeer received his PhD in Biology from the Leiden University Medical Center on a molecular study of DNA damage repair. He subsequently moved to University Medical Center Utrecht to do his Post Doc studying Ras/Rap cancer signaling. During this period, he started working with adult stem cell derived Organoid Technology and developed the first drug screens together with the group of Hans Clevers. He continued this work at Hubrecht Organoid Technology (HUB) where he became responsible for the development of new assays and automation processes.
- Dr Inge Thijssen - van Loosdregt, Field Application Engineer, CytoSMART
- Short bio (~100 words)
- Rob Nixon, Head of Commercial, Qkine
- Short bio (~100 words)
To update shortly with info once have received from all speakers
Dr. Inge Thijssen van Loosdregt is a Field Application Engineer at CytoSMART with a background in life sciences. She has obtained her Ph.D. in soft tissue engineering and mechanobiology at the Eindhoven University of Technology. Inge’s Ph.D. work focused on understanding the forces generated by fibroblasts in order to eventually optimize the design of tissue-engineered heart valves. As a Field Application Engineering, she tests CytoSMART's devices in the lab and works with R&D to keep optimizing and validating the devices in order to fulfill the needs of life science researchers.
Rob Nixon has a strong commercial background in the life science segment with a track record of building and coaching highly successful sales teams. Educated at the University of Manchester, studying BSc (Hons) Medical Biochemistry, he began life at Biotest UK before the pharmaceutical microbiology business was acquired by Merck Millipore. Having worked for Merck in several northern European roles within the laboratory reagents business for over 10 years, he moved to GE Healthcare Life Science to build and drive a new EMEA team focused on applied markets, with a particular focus on the rapidly growing and highly relevant point-of-care lateral flow test market. Latterly, Rob developed a global distributor network for Jellagen’s next-generation collagen to channel into the research market for stem cell and regenerative medicine applications. Rob joined Qkine in April 2020 to implement the commercial go-to-market strategy, channelling Qkine’s growth factor & cytokine portfolio for stem cell culture and organoid research applications.
- Date: Tuesday July 14th
- Time: 4PM CEST (10 AM EDT)
- Duration: 45 minutes
- Interested? Sign up for the webinar here